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The latent membrane protein 2A (LMP2A) of Epstein–Barr virus (EBV) has been implicated in controlling viral latency due
to the ability of LMP2A to block B cell antigen receptor (BCR) signaling in vitro and to alter B cell development and enhance
B cell survival in vivo. These LMP2A functions require interactions with the protein tyrosine kinases Syk and Lyn. However,
a role for the Bruton’s tyrosine kinase (Btk) has not been investigated for these LMP2A functions. To investigate whether Btk
is important for LMP2A developmental and survival signals in vivo, LMP2A transgenic animals were mated to Btk deficient
(Btk2/2) mice. Unlike LMP2A1, Btk1/1 transgenic littermate controls, LMP2A1, Btk2/2 animals do not generate immunoglobulin
(Ig) receptorless B cells in the periphery and instead produce Ig1 B cells similar to those in the Btk2/2 mice. Interestingly,
however, LMP2A1, Btk2/2 animals produce B cells at a vastly reduced level compared to Btk2/2 littermates, indicating that
LMP2A affects B cell development in the absence of Btk. In the RAG-12/2, Btk2/2 double knockout background, LMP2A is still
capable of enhancing the survival of Ig-receptorless B cells. Use of Btk phosphopeptide-specific antibodies reveals that Btk
is constitutively phosphorylated in LMP2A-expressing cell lines. These data indicate that LMP2A initiates both Btk-dependent
and Btk-independent pathways, resulting in altered B cell development and enhanced B cell survival. © 2001 Elsevier Science
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Latent membrane protein 2A (LMP2A) is an Epstein–
Barr virus (EBV) protein that has been implicated in
regulating viral latency within infected B cells (Long-
necker, 2000). In EBV-transformed B cells LMP2A blocks
BCR signal transduction, resulting in a block in activation
of the viral lytic genes (Miller et al., 1995, 1994, 1993).
Structurally, LMP2A is a 497 amino acid long type II
12-membrane-spanning protein with a long cytoplasmic
amino-terminal tail and a shorter cytoplasmic carboxyl-
terminal tail. The amino-terminal tail of LMP2A contains
highly tyrosine-phosphorylated regions and several pro-
line-rich regions that are critical for the ability of LMP2A
to interact with cellular proteins. Phosphorylation at ty-
rosine 112 is important for association between LMP2A
and Src family kinases such as Lyn in vitro (Fruehling et
al., 1998). Phosphorylation at tyrosines 74 and 85, two
key residues in the immunoreceptor tyrosine-based ac-
tivation motif (ITAM) of LMP2A, allows for association
and activation of the PTK Syk in vitro (Fruehling and
Longnecker, 1997). Recent evidence has shown that
Nedd4 ubiquitin ligases associate with two proline-rich
PY motifs within LMP2A in a phosphorylation-indepen-
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46dent manner (Ikeda et al., 2000; Longnecker et al., 2000;
Winberg et al., 2000). These LMP2A-cellular protein as-
sociations enable LMP2A to block BCR crosslinking in
LCLs, leading to a model in which LMP2A maintains viral
latency by blocking normal cellular signaling.
Transgenic mice expressing LMP2A downstream of
the m immunoglobulin (Ig) heavy chain enhancer and
promoter (Em) have highlighted the ability of LMP2A to
impart developmental and survival signals in developing
B cells (Caldwell et al., 2000, 1998). EmLMP2A transgenic
B cells bypass the second step in Ig heavy chain rear-
rangement, resulting in an overall loss of sIg expression.
B cells that lose a functioning BCR have been shown to
rapidly undergo apoptosis (Lam et al., 1997); however,
LMP2A transgenic B cells lacking the BCR are capable of
exiting the bone marrow and persisting in the periphery.
When bred into a RAG-1 deficient background
(RAG-12/2), LMP2A1 B cells are capable of exiting the
bone marrow and persisting in the periphery. These data
indicate that LMP2A drives B cell development and sur-
vival in the absence of normal BCR signals (Caldwell et
al., 2000, 1998). Transgenic mice expressing LMP2A with
a nonfunctional ITAM do not show any developmental or
survival alterations, indicating that an ITAM–Syk interac-
tion is critical for generating developmental and survival
signals in vivo (Merchant et al., 2000).
Activation of the BCR results in the activation of the Src
family kinases, Syk and Btk (for review see Kurosaki,
2000). While LMP2A has been shown to interact with
se in th
ove th
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been delineated. Btk is a member of the Tec family of
tyrosine kinases, consisting of an amino-terminal pleck-
strin homology (PH) domain, a Src homology 2 (SH2)
domain, a SH3 domain, and a catalytic domain (for re-
view see Rawlings, 1999; Satterthwaite and Witte, 2000).
Btk is a 77-kDa protein critical for normal B cell devel-
opment and BCR signaling function. Loss of Btk function
in human B cells results in X-linked agammaglobuline-
mia (XLA), a severe form of immunodeficiency resulting
in the near absence of mature B cells. In mice, loss of Btk
results in a less severe, but multifaceted phenotype
known as X-linked immunodeficiency (xid). The xid phe-
notype in Btk2/2 mice is characterized by loss of perito-
neal B-1 lineage B cells, a slight reduction in conven-
tional B-2 lineage B cell numbers, an increase in the
percentage of B cells displaying an immature cell sur-
face marker phenotype, and the inability of B cells to
respond to a number of B cell mitogens (Khan et al.,
1995).
In this study LMP2A transgenic mice were crossed
into the Btk2/2 background to investigate whether
LMP2A developmental and survival signals are depen-
dent upon Btk. Flow cytometry of bone marrow and
splenocytes were performed to determine whether
LMP2A is capable of altering B cell development and
survival in the absence of Btk. LMP2A, Btk2/2 mice were
further bred into the RAG-12/2 background to determine
whether LMP2A was still capable of enhancing B cell
survival in the absence of both Btk and RAG-1. Finally, the
FIG. 1. Complete loss of the LMP2A in vivo phenotype in the Btk2/2
LMP2A developmental phenotype in the spleen (SP) when bred into th
subjected to flow cytometry analysis using CD19-PE and IgM-FITC anti
CD19high, IgM2 cells with the average percentage of splenic lymphocyte
represents CD191, IgM1 cells, also with the average percentage of
Alteration of the LMP2A1 developmental phenotype in the bone marro
was done as for the spleen. CD191, IgM2 cells were counted as tho
rectangle. Average percentages for each cell population are shown abphosphorylation status of Btk was investigated in
LMP2A1 and LMP2A2 LCLs.RESULTS
Generation of LMP2A1, Btk2/2 mice
Btk2/2 animals bearing a knock-out cassette in the ki-
nase domain of Btk were purchased from Jackson Labora-
tories (Khan et al., 1995) and mated to LMP2A transgenic
line E (TgE) animals. In the TgE line, LMP2A drives B cell
development, resulting in the production of BCR-negative B
cells in the bone marrow and spleen (Caldwell et al., 2000,
1998). TgE animals were bred for two generations until
litters contained WT, TgE, Btk2/2, and TgE, Btk2/2 littermates
as determined by PCR screening for LMP2A, Btk, Neo
(present in the knock-out cassette) and RAG-1 (positive
control) gene fragments. A Btk wild-type background was
defined as animals genotyped Btk1/Y for males and Btk6 or
Btk1/1 for females. Likewise, Btk knockouts were defined as
animals genotyped Btk2/Y for males or Btk2/2 for females.
For simplicity each genotype will be referred to as WT, TgE,
Btk2/2, or TgE, Btk2/2.
Flow cytometric analysis of the LMP2A1, Btk2/2 mice
Spleen and bone marrow samples collected from WT,
TgE, Btk2/2, and TgE, Btk2/2 animals were analyzed by flow
cytometry (Fig. 1). Cells were stained with antibodies to the
pan-B cell marker CD19 and immunoglobulin M (IgM). As
expected, WT animals showed the normal pattern of B cell
development consisting of CD191, IgM2 (54 6 11%) B cells
developing into CD191, IgM1 (30 6 5%) B cells in the bone
marrow. These WT CD191, IgM1 cells colonize peripheral
immune organs, such as the spleen, where most B cells
1 1
ound coupled with a more severe Xid phenotype. (A) Alteration of the
/2 background. WT, TgE, Btk2/2 and TgE, Btk2/2 spleen samples were
. Typical dot plot results are shown. The upper left polygon represents
multiple animals denoted above the polygon. The lower right polygon
lymphocytes from multiple animals denoted above the polygon. (B)
) when bred into the Btk2/2 background. Analysis of the bone marrow
e left rectangle and CD191, IgM1 cells were counted from the right
e boxes.backgr
e Btk2
bodies
s from
splenic
w (BMdisplay a CD19 , IgM phenotype (55 6 7%) with variable
levels of IgM surface expression. In TgE animals most
48 MERCHANT AND LONGNECKERdeveloping bone marrow B cells display a CD191, IgM2
phenotype (70 6 4%) and very few B cells display a CD191,
IgM1 phenotype (4 6 3%). These TgE CD191, IgM2 B cells
exit the bone marrow and colonize the spleen (27 6 13%).
There is a small population of CD191, IgM1 B cells in TgE
animals (8 6 4%). One peculiar aspect of the LMP2A in vivo
phenotype is an increase in CD19 expression levels, lead-
ing to the development of CD19high expressing B cells in
both the bone marrow and the spleen of TgE animals.
Btk2/2 animals display the expected xid phenotype consist-
ing of a slight reduction in CD191, IgM1 B cell numbers in
the bone marrow (26 6 1%) and the spleen (46 6 9%)
compared to WT littermates. The B cells exiting to the
periphery in Btk2/2 mice show an IgMhigh phenotype with
few progressing to the IgMlowIgDhigh mature stage (results
not shown). Furthermore, Btk2/2 mice displayed the ex-
pected lack of IgM1CD51 peritoneal B-1 lineage B cells
(results not shown).
TgE, Btk2/2 animals showed a complete loss of the
LMP2A phenotype and instead display a much stronger xid
phenotype compared to Btk2/2 littermates. In the bone mar-
row of TgE, Btk2/2 mice, there is a reduction in the number
of B cells bearing a CD191, IgM1 phenotype (13 6 3%)
when compared to Btk2/2 littermates. Interestingly, the level
of CD19 is not elevated in TgE, Btk2/2 B cells, perhaps
indicating that Btk is necessary for this aspect of the
LMP2A phenotype. The number of CD191, IgM2 B cells in
the bone marrow are slightly elevated (62 6 9%) compared
to wild-type and Btk2/2 mice (55 and 54%, respectively), but
reduced compared to TgE animals (70%). This slight in-
crease may indicate that LMP2A is altering the balance of
B cell development in the Btk2/2 background. A reduction in
the number of CD191, IgM1 B cells is also observed in the
spleen of TgE, Btk2/2 mice (16 6 6%). These CD191, IgM1
B cells show IgMhigh, IgDlow and IgMhigh, IgDhigh immature
phenotypes as observed in Btk2/2 animals; however, their
numbers are reduced nearly threefold compared to Btk2/2
littermates (46 vs 16%, Student’s t test 5 7.21 3 1029).
These results indicate that Btk is critical for the gen-
eration of two key aspects of the LMP2A in vivo pheno-
type: the bypass of Ig heavy chain rearrangement and
the upregulation of CD19. There is a complete loss of the
CD19high, IgM2 B cells observed in TgE animals, and
instead TgE, Btk2/2 mice display a unique xid phenotype.
This xid phenotype is identical to that seen in Btk2/2
mice; however, the number of IgM1 B cells produced in
the bone marrow and spleen is drastically reduced.
These results indicate that in the absence of Btk, LMP2A
appears to negatively affect the number of B cells capa-
ble of developing and/or surviving.
Alteration of the LMP2A phenotype is not due to loss
of LMP2A expressionTo confirm the absence of Btk expression and proper
expression of LMP2A, immunoblots on WT, TgE, Btk2/2,and TgE, Btk2/2 methyl cellulose cultures were per-
formed (Fig. 2). As previously shown (Caldwell et al.,
2000, 1998; Merchant et al., 2000), WT and TgE animals
produce abundant numbers of B cell colonies in methyl
cellulose containing IL-7. Neither Btk2/2 nor TgE, Btk2/2
bone marrow cells showed any reduction in their ability
to form B cell colonies in this culturing system (data not
shown). Equivalent numbers of methyl cellulose cultured
B cells from each genotype were lysed for analysis by
immunoblot. As expected, WT and Btk2/2 B cells showed
no expression of LMP2A, whereas TgE and TgE, Btk2/2 B
cells show equivalent levels of LMP2A protein expres-
sion (Fig. 2A). EBV1LMP2A2 (ES1)- and EBV1LMP2A1
(LCL)-transformed B cell lines show negative and posi-
tive controls for LMP2A expression, respectively. Simi-
larly, Btk expression is only seen in WT and TgE B cells,
whereas both Btk2/2 and TgE, Btk2/2 B cells show no Btk
expression (Fig. 2B). Both ES1 and LCL lysates show
expression of Btk. PI-3K expression levels are shown to
indicate that protein loading is roughly equivalent (Fig.
2C). These results show that the observed phenotypic
changes are not due to Btk expression or loss of LMP2A
expression.
Flow cytometric analysis of the TgE, Btk2/2, RAG-12/2
mice
The flow cytometry data from TgE, Btk2/2 mice sug-
gested that some LMP2A signals might act indepen-
dently of Btk. However, the de novo expression of IgM in
TgE, Btk2/2 B cells complicates any interpretation of how
Btk-independent LMP2A signals may act. In TgE, Btk2/2 B
cells, survival signals could stem from both the BCR and
the LMP2A. Therefore, to test whether LMP2A is capable
FIG. 2. Confirmation of LMP2A expression and loss of Btk expres-
sion. (A) LMP2A expression in TgE, Btk2/2 bone marrow methyl cellu-
lose cultures. Lysates from methyl cellulose cultures of WT (lane 1),
TgE (lane 2), Btk2/2 (lane 3), and TgE, Btk2/2 (lane 4) bone marrow cells
as well as the EBV1LMP2A2 LCL, ES1 (lane 5) and the EBV1LMP2A2
LCL, LCL1 (lane 6) were subjected to LMP2A Western blot analysis.
The proper size of LMP2A is indicated to the right. (B) Btk expression
in LMP2A 3 Btk2/2 bone marrow methyl cellulose cultures. Western
blot analysis of Btk expression was done on a duplicate gel to that
shown in (A). The proper size of Btk is indicated to the right. (C) PI-3K
expression in LMP2A 3 Btk2/2 bone marrow methyl cellulose cultures.
Western blot analysis for PI-3K was done on the upper half of the gel
shown in (A). The proper size of PI-3K p85 is shown to the right.of initiating B cell survival signals independently of Btk,
TgE, Btk2/2 animals were bred into the recombinase
ells, wh
49Btk DEPENDENCE OF LMP2A SIGNALSactivating gene-1 knock-out (RAG-12/2) background.
RAG-12/2 animals do not develop any lymphocytes due
to the inability to recombine the genes coding for the B
cell and T cell receptors (Mombaerts et al., 1992). All
LMP2A transgenic animals containing a functional ITAM
are capable of providing developmental and survival
signals in the RAG-12/2 background (Caldwell et al.,
2000, 1998; Merchant et al., 2000). The creation of
LMP2A1, Btk2/2, RAG-12/2 B cells therefore tests whether
LMP2A developmental and survival signals act indepen-
dently of both Btk and the BCR.
Spleen and bone marrow samples from WT and TgE
animals bred into the C57BL/6 (WT), RAG-12/2, Btk2/2
and RAG-12/2, Btk2/2 backgrounds were analyzed by flow
cytometry for CD19 and IgM expression (Fig. 3). WT
1 2
FIG. 3. LMP2A is capable of enhancing B cell survival in the absenc
stained with CD19-PE and IgM-FITC from WT and TgE animals (Ge
background (Bkgd. 5 background, top). The left polygon represents CD
Average percentages for each cell population are shown above the b
CD19-PE and IgM-FITC from WT and TgE animals (Geno. 5 genotype,
5 background, top). The left rectangle represents CD191, IgM2 B c
percentages for each cell population are shown above the boxes.animals show the progression from CD19 , IgM (47%)
to CD191, IgM1 (40%) in the bone marrow, ultimatelyresulting in a large population of CD191, IgM1 cells in
the periphery (52%). In contrast, TgE B cells remain
largely CD191, IgM2 in the bone marrow (81%) and
spleen (18%). In the RAG-12/2 background, LMP2A allows
for the production and survival of CD191, IgM2 B cells in
the bone marrow (66%) and the spleen (57%). The per-
centage of CD191, IgM2 cells is higher in TgE, RAG-12/2
background due to the loss of T cells, not an increase in
B cell production. There is a small population of CD191,
IgM2 cells in the bone marrow of RAG-12/2 animals
(21%); however, these cells do not exit the bone marrow
(1% in spleen). Again, Btk2/2 animals show slightly de-
creased B cell levels (47% in spleen) and the character-
istic xid phenotype while TgE, Btk2/2 animals produce
CD191, IgM1 B cells in the bone marrow and the spleen
2/2
th Btk and the BCR. (A) Flow cytometry data from spleen (SP) samples
genotype, left) in the C57BL/6, RAG-12/2, Btk2/2 or RAG-12/2, Btk2/2
M2 B cells, whereas the right polygon represents CD191, IgM1 B cells.
) Flow cytometry data from bone marrow (BM) samples stained with
the C57BL/6, RAG-12/2, Btk2/2 or RAG-12/2, Btk2/2 background (Bkgd.
ereas the right rectangle represents CD191, IgM1 B cells. Averagee of bo
no. 5
191, Ig
oxes. (B
left) in(24%) in vastly reduced numbers compared to Btk
mice. Similar to RAG-12/2 mice, Btk2/2, RAG-12/2 animals
50 MERCHANT AND LONGNECKERalso produce very few CD191, IgM2 B cells in the bone
marrow and these cells do not progress to the periphery.
However, in TgE, Btk2/2, RAG-12/2 animals, LMP2A al-
lows for the development of a large population of CD191,
IgM2 B cells in the bone marrow (65%), a small number
of which are capable of exiting the bone marrow and
colonizing the spleen (23%). The percentage of CD191,
IgM2 B cells produced in TgE, Btk2/2, RAG-12/2 animals
is much less than the number observed in TgE, RAG-12/2
mice (57%). It is also interesting to note that the cells that
are produced in the TgE, Btk2/2, RAG-12/2 background do
not display a CD19high phenotype, but rather maintain
CD19 at normal levels.
Analysis of Btk phosphorylation
The results from TgE, Btk2/2 and TgE, Btk2/2, RAG-12/2
animals suggest that LMP2A is utilizing Btk to initiate
signals ultimately resulting in B cell development and
survival in vivo. Btk activation occurs in two steps, with
Y551 first becoming phosphorylated by Src family ki-
nases, followed by autophosphorylation at Y223 (Li et al.,
1997; Nisitani et al., 1999). To test whether LMP2A acti-
vates Btk, unstimulated EBV1LMP2A2 (ES1) and
EBV1LMP2A1 (B2.WT) lysates were subjected to immu-
noprecipitations using a Btk amino-terminal antibody
(Btk-NT IP) followed by Western blot analysis with Btk
phosphopeptide-specific antibodies to tyrosines 223 and
551 of Btk (PY223 and PY551). In resting EBV1LMP2A2
FIG. 4. Btk is constitutively phosphorylated on tyrosines 223 and 551
in LMP2A expressing LCLs, but not LMP2A-negative LCLs. (A) Y223
phosphopeptide-specific Western blot on LMP2A-negative (ES1, lane 1)
LCLs and LMP2A-expressing (B2.WT, lane 2). Immunoprecipitations
(IPs) using the Btk amino-terminal (NT) antibody were subjected to
SDS–PAGE, and Western blotted with a-PY223 phosphopeptide-spe-
cific Btk antibodies. Btk IPs from stable cell lines bearing Btk point
mutants with tyrosines 223 and 551 changed to phenylalanine (Y223F
and Y551F, respectively) are shown as controls for the phosphopeptide
specific antibodies. Only Btk-Y551F (lane 4) shows a band in (A),
showing that this antibody recognizes Y223, but not Y551 of Btk. (B)
Y551 phosphopeptide-specific Western blot analysis was done on a
duplicate gel from (A). Only Btk-Y223F (lane 3) shows a band in (B),
showing that this antibody recognizes Y551, but not Y223 of Btk.ES1 cells, Btk shows little appreciable Btk phosphoryla-
tion on Y223 or Y551 (Figs. 4A and 4B). In contrast,resting EBV1LMP2A1 B2.WT cells show constitutive
phosphorylation of Btk at tyrosines 223 and 551. Immu-
noprecipitations of Btk from stable cell lines bearing the
tyrosine point mutants Btk-Y223F and Btk-Y551F show the
specificity of the Btk phosphopeptide-specific antibod-
ies. These data show that LMP2A expression in human
B cells leads to constitutive phosphorylation of Btk at
both regulatory tyrosines.
DISCUSSION
The phenotypes observed in LMP2A, Btk2/2 mice in-
dicate that LMP2A development and survival signals are
transmitted in both Btk-dependent and independent
pathways. These data further add to our understanding
of how LMP2A signals lead to the observed in vivo
phenotypes (Fig. 5). B cell development occurs in a
well-defined stepwise developmental progression that
includes pro-B, pre-B, immature, and mature stages (Fig.
5A; Hardy and Hayakawa, 1995; Hardy et al., 2000; Ha-
yakawa et al., 1997). LMP2A signals alter normal B cell
development by bypassing normal Ig heavy chain rear-
rangement and increasing CD19 expression levels (Cald-
well et al., 2000, 1998). These signals ultimately result in
a developmental bypass coupled with the survival of
BCR-negative B cells in the spleen (Caldwell et al., 2000,
1998). In the absence of Btk, a multistage xid defect in B
cell maturation and functional response occurs (Khan et
al., 1995). When LMP2A is expressed in the Btk2/2 back-
ground, there is a complete loss of the LMP2A in vivo
phenotypes, including the bypass in Ig heavy chain re-
arrangement and upregulation of CD19. Interestingly, in
TgE, Btk2/2, RAG-12/2 mice, a partial restoration of the
LMP2A in vivo phenotypes is observed, indicating that an
interplay between LMP2A and BCR signals underlies the
novel phenotypes observed in the immunocompetent
background.
There are three general mechanisms to account for
the observed increase in severity of the xid phenotype in
TgE, Btk2/2 mice. All of these mechanisms relate to how
B cells interpret the signals from both the LMP2A and the
BCR in the LMP2A1, Btk2/2 animals during B cell devel-
opment and survival in the periphery (Fig. 5A). In the first
situation, occurring during early B cell development,
LMP2A signals may act in concert with the normal BCR
signals, causing a shift in the apparent “strength of sig-
nal” downstream of the BCR. B cells that experience a
strong BCR signal undergo deletion during development,
insuring the absence of autoreactive B cells (Hartley et
al., 1991, 1993). In this way, combined LMP2A and BCR
signals could lead to increased B cell deletion early
during development. This would seem unlikely due to the
large numbers of B cells in the bone marrow samples. In
the second case, LMP2A may actually interfere with
normal BCR signaling, resulting in B cell apoptosis (Fig.
5A). This effect could occur during development or once
51Btk DEPENDENCE OF LMP2A SIGNALSFIG. 5. B cell development in TgE, Btk2/2 and TgE, Btk2/2, RAG-12/2 mice. (A) Normal B cell development in wild-type (WT) mice occurs in a multistep
process involving progression of cells through the pro-B, pre-B, and immature stages within the bone marrow, finally resulting in the generation of
mature B cells in the spleen (top). CD19 is a pan-B cell marker arising early in B cell development. Immunoglobulin genes rearrange during the pre-B
cell stage leading to the expression of IgM on the cell surface. This is followed by the expression of both IgM and IgD on the cell surface. The levels
of IgM and IgD change over the maturation process, ultimately resulting in mature IgMlow IgDhigh B cells in the periphery. In LMP2A transgenic line
E (TgE) animals, both Btk-dependent and Btk-independent LMP2A signals lead to a bypass of Ig gene rearrangement and the upregulation of CD19.
These CD19high, IgM2 B cells are capable of exiting the bone marrow and entering the spleen. Btk2/2 mice display an X-linked immunodeficient (xid)
phenotype characterized by a slight reduction in the number of total B cells in the spleen. These B cells display an immature IgMhigh, IgDhigh/low
phenotype and show refractory responses to a variety of stimuli. In TgE, Btk2/2 mice, there is a loss of the LMP2A-dependent bypass in Ig gene
rearrangement and no abnormal increase in CD19 expression levels. As the TgE, Btk2/2 B cells develop, both LMP2A and B cell antigen receptor (BCR)
signals may be transmitted, leading to a scenario where B cells need to integrate and interpret both signals. The LMP2A signals negatively affect
the number of B cells produced in the bone marrow and spleens of TgE, Btk2/2 mice though a mechanism involving increased deletion, increased
cell death, or slower B cell production. (B) In the recombinase-activating gene 1 knock-out (RAG-12/2) background, B cell development is normally
halted at the pro-B to pre-B checkpoint due to the inability to recombine a functional BCR. LMP2A is capable of generating Btk-dependent and
Btk-independent signals in TgE, RAG-12/2 B cells that act to upregulate CD19 levels and bypass the pro-B to pre-B cell developmental checkpoint,
leading to the generation of CD19high, IgM2 B cells in the periphery. Similar to RAG-12/2 B cells, RAG-12/2, Btk2/2 B cells are also stopped at the pro-B
to pre-B cell checkpoint. However, Btk-independent LMP2A signals in TgE, RAG-12/2, Btk2/2 mice allow for the production of CD191, IgM2 B cells in
2/2 2/2 2/2the spleen. The reduction in the number of B cells observed in TgE, RAG-1 , Btk spleens compared to TgE, RAG-1 spleens is most likely due
to increased cell death in the periphery, reduced B cell production, or reduced exit of B cells from the bone marrow.
52 MERCHANT AND LONGNECKERB cells colonize the periphery. B cells absolutely require
constant BCR signals to develop and survive (Gong and
Nussenzweig, 1996; Kitamura et al., 1991; Lam et al.,
1997; Mombaerts et al., 1992; Shinkai et al., 1992). Finally,
the reduced levels of B cells in TgE, Btk2/2 mice may
occur because there is a reduction in the rate at which
IgM1 B cells are produced or at which they exit the bone
marrow. The slight increase in the number of CD191,
IgM2 B cells in TgE, Btk2/2 bone marrow (Fig. 1) may
indicate that B cells at the pre-B stage are accumulating
due to a reduction in the rate at which B cells exit to the
periphery. This would seem unlikely because of the ob-
served reduction in IgM1 cells in the bone marrow of
TgE, Btk2/2 mice. Regardless of the mechanism, it ap-
pears that increased cell death during B cell develop-
ment results in the observed phenotype in TgE, Btk2/2
mice.
Breeding TgE, Btk2/2 mice into the RAG-12/2 back-
ground allowed for the isolation of LMP2A signals from
those of the BCR, enabling the investigation of whether
LMP2A enhances survival independent of Btk. RAG-12/2
mice do not progress past the pro-B cell stage of devel-
opment due to the inability to recombine Ig and form a
cognate BCR (Mombaerts et al., 1992). TgE, RAG-12/2
mice are able to bypass this strong developmental block
and produce CD19high B cells in the periphery (Caldwell
et al., 2000, 1998). Loss of both Btk and RAG-1 results in
mice functionally identical to RAG-12/2 mice with the
absence of B cells progressing past the pro-B cell stage.
In the absence of both Btk and RAG-1, LMP2A is still
capable of supporting the production of CD191, IgM2 B
cells in the bone marrow, a small proportion of which are
capable of exiting to and/or surviving in the periphery.
The level of CD19 is not upregulated in TgE, Btk2/2,
RAG-12/2 B cells, indicating that this aspect of the
LMP2A in vivo phenotype is Btk-dependent. The reduc-
tion in the number of CD191, IgM2 splenic B cells ob-
served in TgE, Btk2/2, RAG-12/2 mice compared with
those in TgE, RAG-12/2 mice indicates that Btk plays an
important role in the immigration to or survival of these
cells in the periphery.
Together with Syk, Btk has been shown to upregulate
the function or transcription of antiapoptotic proteins,
such as Akt and members of the Bcl-2 family (Anderson
et al., 1996; Cariappa et al., 1999; Craxton et al., 1999;
Kawakami et al., 1997; Woodland et al., 1996). Several
studies have shown that cells expressing LMP2A show
constitutive PI-3K and Akt phosphorylation (Miller et al.,
1993; Scholle et al., 2000; Swart et al., 2000). Akt activa-
tion has also been shown to be dependent upon Syk and
Btk function in DT40 chicken B cells bearing knockouts
for these factors (Craxton et al., 1999). Akt could be
acting as a critical antiapoptotic factor downstream of an
LMP2A-Btk signal, thus explaining the enhanced survival
2/2signal observed of TgE and TgE, RAG-1 B cells. Btk
has also been linked to increased Bcl-2 and Bcl-xl func-tion (Anderson et al., 1996). Expression of Bcl-2 in the B
cells of Xid mice show a complete reversion of the xid
phenotype, indicating that Btk normally acts to upregu-
late Bcl-2 function in vivo (Woodland et al., 1996). Fur-
thermore, a Bcl-2 transgene is capable of enhancing the
survival, but not the development, of immature B cells in
vivo (Tarlinton et al., 1997; Young et al., 1997). Further
work needs to be done to address any roles for Akt or
members of the Bcl-2 family in enhancing B cell survival
in vivo.
One caveat of the results presented in this report is
that Btk appears to be less critical for B cell development
and function in mice compared to humans. Mutation of
Btk in humans leads to the severe immunodeficiency
XLA, whereas mutation of Btk in mice leads to the milder
X-linked immunodeficiency (Satterthwaite et al., 1998;
Satterthwaite and Witte, 2000; Tsukada et al., 1993; Vetrie
et al., 1993; Zhu et al., 1994). This difference may be due
to the ability of Tec, a related kinase, to act in a redun-
dant fashion to Btk with respect to development and
signal transduction (Ellmeier et al., 2000; Kitanaka et al.,
1998). Loss of both Btk and Tec in mice leads to a near
absence of B cells, similar to what is observed in XLA
patients (Ellmeier et al., 2000). If LMP2A utilizes the Tec
kinase, essentially acting to sequester it from normal B
cell signaling during development, this might help ac-
count for the more severe phenotype observed in TgE,
Btk2/2 mice compared to Btk2/2 mice. B cells from XLA
patients have been used to establish EBV-transformed
LCLs (Fluckiger et al., 1998; Kitanaka et al., 1998; Mallone
et al., 1998), indicating that EBV infection and transfor-
mation is not affected by loss of Btk. Interestingly, XLA
LCLs lacking Btk expression also show high expression
of Tec (Kitanaka et al., 1998). However, evidence for
EBV-related pathogenesis in XLA patients is scarce. Un-
derstanding the role of Btk and other specific kinases in
LMP2A-dependent signaling may allow for the develop-
ment and use of specific kinase inhibitor treatments to
block LMP2A function and perhaps EBV latency in vivo.
MATERIALS AND METHODS
Mice
Construction and characterization of Em LMP2A trans-
genic, RAG-12/2, and Btk2/2 mice has been previously
described (Caldwell et al., 1998; Khan et al., 1995; Mom-
baerts et al., 1992). Btk2/2 (B6.129S7-Btktm1Wk) and
RAG-12/2 (B6.129S7-Rag1tm1Mom) animals were obtained
from Jackson Laboratories. All animals were housed at
the Northwestern University Center for Experimental An-
imal Resources in accordance with university animal
welfare guidelines.
Tail DNA isolation and PCRDNA preparation and polymerase chain reaction (PCR)
analysis for the presence of the LMP2A transgene,
53Btk DEPENDENCE OF LMP2A SIGNALSRAG-1, and the neomycin was done as previously de-
scribed (Caldwell et al., 2000, 1998; Merchant et al.,
2000). Presence of the Btk gene was determined using a
PCR protocol from the Jackson Laboratories utilizing the
primers oMLR367 (59-CAGAGAAGGTTCCATGTCGG-39)
and oMLR368 (59-GCCATTAGCCATGTACTCGG-39).
Flow cytometry
Flow cytometry was done as previously described
(Caldwell et al., 2000, 1998; Merchant et al., 2000). All
antibodies were purchased from BD Pharmingen. Sam-
ples were run on a Becton Dickinson FACScan and data
were analyzed using CellQuest software.
Methyl cellulose culturing of bone marrow B cells
Methyl cellulose media containing IL-7 for the produc-
tion of murine pre-B cells from StemCell Technologies
(MethoCult M3630) was used as previously described
(Caldwell et al., 2000, 1998; Merchant et al., 2000). Total
bone marrow cells (1 3 106) isolated in sterile RPMI
media containing 1% fetal calf serum and 1% penicillin/
streptomycin were vortexed into 3 mL MethoCult M3630
media, plated into two 35 3 10 mm tissue culture Petri
dishes, and incubated for 1 week at 37°C and 5% CO2.
Following culturing, B cells were washed in 13 PBS
three times, cell number determined, and lysates pre-
pared for immunoblotting.
Protein isolation and Western blotting
Spleen and bone marrow samples were prepared as
previously described (Caldwell et al., 2000, 1998; Mer-
chant et al., 2000). All samples were subjected to heat
denaturation at 70°C for 10 min, loaded onto 8% SDS–
polyacrylamide gels, and run at 100 V for 1.5 h. Gels were
transferred onto Immobilon (Millepore) and immunoblot-
ted. LMP2A was detected using a rat monoclonal anti-
body (14B7-1-1 at 2.8 mg/ml) at 1:2500. For mouse spleen
lysates, Btk was detected using rabbit polyclonal a-Btk
antibodies with reactivity against the N-terminal portion
of Btk from BD Pharmingen (Cat. 65251A at 1 mg/ml) at
1:250. The p85 subunit of PI-3K was detected using
rabbit polyclonal a-p85 PI-3K antibodies with reactivity
against PI-3K from Upstate Biotechnology (Cat. 06-195 at
1 mg/ml) at 1:5000. Btk N-terminal, BtkPY223, and
BtkPY551 phosphopeptide-specific antibodies were gen-
erously provided by Dr. Matthew Wahl and Dr. Owen
Witte from the University of California-Los Angeles. Btk
immunoprecipitation (IP) experiments were done using 1
mg of Btk NT antibodies bound to a mixture of protein A
and protein G Sepharose beads. Following gel separa-
tion and blotting, Btk IPs were blotted using antibodies
specific for Btk-PY223 (;0.7 mg/ml) and Btk-PY551 (;0.3
mg/ml) each at 1:1000. Stable cell lines bearing mutant
BtkY223F and BtkY551F have been described previously
(Nisitani et al., 1999). Dr. Matthew Wahl and Dr. OwenWitte kindly provided Btk IPs from BtkY223F and
BtkY551F stable cell lines.
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